T-cell receptor alpha-beta complex (TCRαβ) (TCRαβ)

The T-cell receptor (TCR) alpha-beta complex is a multimeric transmembrane protein complex found on the surface of the majority of T lymphocytes, where it serves as the primary mediator of antigen recognition [1.1.1, 1.2.1]. It consists of a disulfide-linked heterodimer of alpha (α) and beta (β) chains that non-covalently associate with the CD3 signaling apparatus, including the CD3γε, CD3δε, and CD3ζζ subunits [1.1.3, 1.3.2]. The complex functions by recognizing specific peptide fragments presented by major histocompatibility complex (MHC) molecules on the surface of antigen-presenting or target cells, thereby initiating a signaling cascade that leads to T-cell activation, proliferation, and effector function [1.1.1, 1.3.1]. In the context of disease, the TCR is a critical driver of both protective immunity against pathogens and pathological responses in autoimmunity and cancer [1.1.1, 1.3.2]. Therapeutically, the TCR alpha-beta complex is targeted through adoptive cell therapies, such as TCR-engineered T cells (TCR-T), and soluble bispecific molecules like tebentafusp, which redirect T-cell cytotoxicity toward tumor-specific antigens [1.1.2, 1.4.2]. However, manipulating this complex carries significant risks, including cytokine release syndrome (CRS) and potential off-target toxicities due to cross-reactivity with healthy tissues [1.1.2, 1.4.3].

Other names

αβ T-cell receptorTCR alpha/betaTCR-CD3 complexT-cell antigen receptorAlpha-beta T-cell receptor

The mechanism of action involves the redirection of T-cell cytotoxic activity through engineered TCRs or bispecific engagers that bind specific peptide-MHC complexes, or the modulation of T-cell signaling via the associated CD3 subunits to induce immunosuppression or activation [1.1.2, 1.1.4, 1.4.2].